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 Pulmonary Hypertension Surveillance 
 United States, 2001 to 2010 
 Mary G.  George ,  MD ;  Linda J.  Schieb ,  MSPH ;  Carma  Ayala ,  PhD ;  Anjali  Talwalkar ,  MD ; and  Shaleah  Levant ,  MPH 
 Pulmonary hypertension (PH) is an uncommon but progressive condition, and much of what 
we know about it comes from specialized disease registries. With expanding research into the 
diagnosis and treatment of PH, it is important to provide updated surveillance on the impact 
of this disease on hospitalizations and mortality. This study, which builds on previous PH 
surveillance of mortality and hospitalization, analyzed mortality data from the National Vital 
Statistics System and data from the National Hospital Discharge Survey between 2001 and 
2010. PH deaths were identiﬁ ed using  International Classiﬁ cation of Diseases, Tenth Revision 
codes I27.0, I27.2, I27.8, or I27.9 as any contributing cause of death on the death certiﬁ -
cate. Hospital discharges associated with PH were identiﬁ ed using  International Classiﬁ cation 
of Diseases, Ninth Revision, Clinical Modiﬁ cation codes 416.0, 416.8, or 416.9 as one of up 
to seven listed medical diagnoses. The decline in death rates associated with PH among men 
from 1980 to 2005 has reversed and now shows a signiﬁ cant increasing trend. Similarly, the 
death rates for women with PH have continued to increase signiﬁ cantly during the past 
decade. PH-associated mortality rates for those aged 85 years and older have accelerated com-
pared with rates for younger age groups. There have been signiﬁ cant declines in PH-associated 
mortality rates for those with pulmonary embolism and emphysema. Rates of hospitalization 
for PH have increased signiﬁ cantly for both men and women during the past decade; for 
those aged 85 years and older, hospitalization rates have nearly doubled. Continued surveil-
lance helps us understand and address the evolving trends in hospitalization and mor-
tality associated with PH and PH-associated conditions, especially regarding sex, age, and 
race/ethnicity disparities.  CHEST 2014; 146(2):476- 495 
 ABBREVIATIONS:  AAPC  5 average annual percent change; AI/AN  5 American Indian/Alaska native; 
APC  5 annual percent change;  ICD-9-CM  5  International Classification of Diseases, Ninth Revision, 
Clinical Modification ; ICD-10  5  International Classification of Diseases, 10th Revision ; NH  5 non-
Hispanic; NHDS  5 National Hospital Discharge Survey; NIH  5 National Institutes of Health; PAH  5 
pulmonary arterial hypertension; PH  5 pulmonary hypertension; REVEAL Registry  5 Registry to Eval-
uate Early and Long-term PAH Disease Management; UCOD  5 underlying cause of death 
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 Pulmonary hypertension (PH) is an 
uncommon but progressive condition. In 
the past, it has been called an orphan 
disease because it aff ects small numbers of 
individuals, is associated with many dis-
eases, and is oft en overlooked by doctors. 1 
Previous surveillance from the Centers for 
Disease Control and Prevention 2 from 1980 
Open access under CC BY-NC-ND license.
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 Materials and Methods 
 Mortality 
 Mortality data from the National Vital Statistics System for the period 
2001 to 2010 were analyzed. Bridged-race July 1 population estimates 
produced by the US Census Bureau in collaboration with the National 
Center for Health Statistics were compiled using intercensal estimates 
for the period 2001 to 2009 and postcensal estimates for 2010. For this 
report, all diseases and conditions reported on death certifi cates were 
classifi ed according to codes from the  International Classifi cation of 
Diseases, 10th Revision (ICD-10). For this analysis, PH deaths are 
defi ned as those with decedents having ICD-10 codes I27.0, I27.2, I27.8, 
or I27.9 reported as any contributing cause of death (ie, any of the pos-
sible 20 conditions, including underlying cause) on the death certifi cate. 
An ICD coding change for mortality occurred in 2003 with the addition 
of ICD-10 code I27.2 for secondary PH. Th is resulted in a shift  from 
coding most cases of death related to PH from primary PH (ICD-10 
I27.0) to other secondary PH ( Fig 1 , 12  Table 2 ). Th ese changes require 
careful interpretation of PH surveillance data over time when relying 
on individual ICD-10 codes. 13 
 Rates are expressed per 100,000 population and were directly age stan-
dardized to the 2000 US standard population and eight age groups 
(0-12 months followed by those aged 1 to 34 years, 35 to 44 years, 45 to 
54 years, 55 to 64 years, 65 to 74 years, 75 to 84 years, and   85 years). 
Age-standardized death rates and 95% CIs were calculated by sex, race/
ethnicity (ie, non-Hispanic [NH] white, NH black, NH American Indian 
or Alaska native (AI/AN), NH Asian/Pacifi c Islander, Hispanic), and 
the decedent’s state of residence at time of death. Age-specifi c death 
rates were calculated. It should be noted that race and ethnicity may not 
be captured accurately on the death certifi cate, especially for Hispanics 
and races other than black or white. 14 This may affect the observed 
death rates for Hispanics and other nonwhite/nonblack individuals, 
especially AI/AN decedents. 
 Trend analyses and comparability tests for age-standardized or age-
specifi c death rates plotted over time by year were conducted using 
Joinpoint soft ware, developed by the National Cancer Institute. (Join-
point version 4.0.3; National Cancer Institute). Th e number of trend 
segments is based on a segmented line regression analysis of best fi t 
with the smallest number of “joinpoints” or points (0 or 1) at which 
the direction of the trend line changes. Annual percent change (APC) 
was calculated for each of the trend segments. Average annual percent 
change (AAPC) was calculated for the time period 2001 to 2010 to 
quantify the average trend over this time period. To determine whether 
the trend lines were parallel or coincident, tests were conducted to 
assess pairwise diff erences between race/ethnicity, with NH white as 
the referent; age-specifi c diff erences, with 0 to 12 months as the ref-
erent; and sex diff erences, with men as the referent. Tests determined 
whether (1) two joinpoint regression functions were identical (test of 
coincidence) or (2) two regression mean functions were parallel (test of 
parallelism) at  P  , .05. 
 Th e distribution of selected disease categories reported as the under-
lying cause of death (UCOD) among decedents with reported PH 
was examined for 2001 through 2010 by race/ethnicity and sex. Rates 
and trends for these distributions were calculated over that time 
period. 
 Hospitalizations 
 The NHDS, conducted annually from 1965 to 2010 by the Centers 
for Disease Control and Prevention’s National Center for Health 
to 2002 identifi ed decreasing mortality rates associated 
with PH among men, but increasing mortality rates 
among women, along with stable rates among whites but 
increasing rates among blacks. Increasing rates of hospi-
talization associated with PH were identifi ed as well. Th e 
symptoms of PH during the initial stage of the disease 
are common to many other medical conditions (eg, dif-
fi culty breathing, fatigue), oft en resulting in a delayed 
diagnosis until more severe symptoms arise (eg, dizzi-
ness, chest pain, ankle swelling, palpitations). 3,4 
 PH is characterized by increased pressure in the pulmo-
nary arteries (resting mean pulmonary artery pres-
sure   25 mm Hg) and increased pulmonary arterial 
resistance but it is associated with many underlying con-
ditions. 5 Th e World Health Organization classifi cation 
of PH, known as the Dana Point classifi cation, was last 
updated in 2008 6 ( Table 1 ), aft er the most recent PH sur-
veillance summary from the Centers for Disease Control 
and Prevention. 2 Some common underlying causes 
include pulmonary arterial hypertension (PAH) from 
congenital heart disease, connective tissue disease, or 
persistent PH of the newborn; PH due to left -sided heart 
disease; chronic lung diseases and hypoxemia; and 
chronic thromboembolic pulmonary disease. Genetics 
also plays a role in PH, and although PH occurs at all ages, 
the incidence increases with age. Registries from France 
and the United Kingdom report an incidence rate of 1.1 to 
2.4 cases per million population per year, a prevalence 
of 6.6 to 15.0 cases per million population per year for 
PAH, and a 5-year mortality of approximately 40%. 7 
 Much of what we know about PH comes from special-
ized disease registries. 8-10 With expanding research into 
the diagnosis and treatment of PH, it is important to 
provide updated surveillance on the impact of this 
disease on hospitalizations and mortality. Th e surveil-
FOR EDITORIAL COMMENT SEE PAGE  239 
SEE RELATED ARTICLE PAGE  449 
lance report by Hyduk et al 2 described trends in mor-
tality and hospitalization rates associated with PH 
among adults aged 45 years and older from 1980 
through 2002 by demographic characteristics. Th is 
study builds on previous PH surveillance of mortality 
and hospitalization using data from the National Vital 
Statistics System and the National Hospital Discharge 
Survey (NHDS). 11 Th e purpose of our report is to 
describe trends in diagnosed PH-related mortality and 
hospitalizations during the period 2001 to 2010. Because 
PH is frequently reported as a secondary diagnosis, our 
report presents data for PH as any contributing cause of 
death or as any listed hospital diagnosis. 
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 TABLE 1  ]  World Health Organization Dana Point Classifi cation of Pulmonary Hypertension (2008) 
Classiﬁ cation
1. Pulmonary arterial hypertension 
 1.1. Idiopathic
 1.2. Heritable
  1.2.1. BMPR2
  1.2.2. ALK1 endoglin (with or without hereditary hemorrhagic telangiectasia
  1.2.3. Unknown
 1.3. Drug and toxin induced
 1.4. Associated with
  1.4.1. Connective tissue diseases
  1.4.2. HIV infection
  1.4.3. Portal hypertension
  1.4.4. Congenital heart diseases
  1.4.5. Shistosomiasis
  1.4.6. Chronic hemolytic anemia
 1.5. Persistent pulmonary hypertension of the newborn
 1.6. Pulmonary venoocclusive disease
2. Pulmonary hypertension owing to left-sided heart disease
 2.2. Systolic dysfunction
 2.2. Diastolic dysfunction
 2.3. Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
 3.1. COPD
 3.2. Interstitial lung disease
 3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
 3.4. Sleep-disordered breathing
 3.5. Alveolar hypoventilation disorders
 3.6. Chronic exposure to high altitude
 3.7. Development abnormalities
4. Chronic thromboembolic pulmonary hypertension
5. Pulmonary hypertension with unclear multifactorial mechanisms
 5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
 5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans’ cell histiocytosis
 5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
 5.4. Others: tumoral obstruction fi brosing mediastinitis, chronic renal failure or dialysis
 ALK1  5 activin receptor-like kinase type 1; BMPR2  5 bone morphogenetic protein receptor type 2. (Adapted with permission from Simonneau et al. 6 ) 
Statistics, is a national probability sample survey of hospital discharge 
information abstracted from the medical records of inpatients from 
nonfederal, short-stay general hospitals in the United States. 15 Only 
hospitals with an average length of stay of fewer than 30 days for all 
patients, and general and children’s general hospitals, were included 
in the survey. Excluded were federal, military, and Veterans Aff airs 
hospitals, as well as hospital units of institutions, such as prison hos-
pitals, and hospitals with fewer than six beds staff ed for patient use. 
NHDS data from 2001 to 2010 were analyzed in fi ve 2-year incre-
ments (2001-2002, 2003-2004, 2005-2006, 2007-2008, and 2009-2010). 
Annual discharge and population estimates were combined in 2-year 
intervals to increase the reliability of rate estimates. Th is report pro-
vides estimates of the number and rates of hospitalization discharges 
attributed to PH, defi ned as having any one of up to seven listed med-
ical diagnoses with an  International Classifi cation of Diseases, Ninth 
Revision, Clinical Modifi cation (ICD-9-CM) code of 416.0, 416.8, or 
416.9. In 2010, a change occurred in the ICD-9-CM codes for PH, 
with the addition of a code for chronic pulmonary embolism (416.2). 
Estimates of the number and rate of hospitalizations associated with 
PH were calculated by using weights (ie, infl ation factors) that allowed 
national estimation from the sample. More details about the design of 
NHDS have been published elsewhere. 15 Because people with multiple 
discharges during the year may be sampled more than once, esti mates 
are for hospital discharges, not persons. Data for newborn infants, defi ned 
as patients admitted to a hospital by birth, were excluded from this 
report. 
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 Results 
 Mortality 
 Th e death rate for PH as any contributing cause of death 
was 5.5 per 100,000 in 2001 and 6.5 per 100,000 in 2010 
( Tables 3, 4 ). PH death rates for men and women were 
the same in 2001 (5.6 per 100,000). Although rates have 
increased for both men and women, the AAPC in death 
rates from 2001 to 2010 shows that rates rose more 
sharply for women (AAPC, 2.5;  P  , .05) than for men 
(AAPC, 0.9;  P  , .05) ( Fig 2 ,  Table 5 ). Although there 
was a 1.3% annual decrease in PH death rates among 
men from 2001 to 2006, this was followed by a signifi -
cant increase (APC, 3.7;  P  , .05) from 2006 to 2010. 
PH death rates among women show signifi cant 
increases during both time segments (APC, 1.7 in 
2001-2006 and 3.5 in 2006-2010). Overall, trends in 
PH deaths increased signifi cantly only from 2006 to 
2010, with an APC of 3.6 ( P  , .05) and a total 
AAPC from 2001 to 2010 of 1.9 (95% CI, 1.5-2.4) 
( Fig 2 ,  Table 5 ). 
 From 2001 to 2010, PH death rates were consistently 
higher for NH blacks than for NH whites (2010 rate, 
9.1 per 100,000 for NH blacks vs 6.5 per 100,000 for NH 
whites) ( Tables 3, 4 ). When compared with those for 
NH whites, PH death rates for NH AI/AN, NH Asian/
Pacifi c Islanders, and Hispanics were consistently either 
lower or not statistically signifi cantly diff erent. How-
ever, it should be noted that because of concerns 
regarding the accuracy of coding race/ethnicity on death 
certifi cates, the comparisons of NH whites with race/
ethnic groups other than NH blacks are provided with 
caution on interpretation. 18 PH death rates increased 
over time for all races/ethnicities ( Fig 3 ,  Table 6 ). For 
NH whites, PH deaths did not increase during the fi rst 
time segments from 2001 to 2006 (APC, 0.5) but 
increased signifi cantly from 2006 to 2010 (APC, 3.8; 
 P  , .05). NH blacks experienced a signifi cant increase in 
death rates during the entire time period from 2001 to 
2010 (APC, 2.3;  P  , .05), as did NH AI/AN and NH 
Asian/Pacifi c Islanders (APC, 4.0 and 3.7, respectively; 
 P  , .05). Although there was no signifi cant change in 
PH death rates among Hispanics from 2001 to 2007 
(APC, 0.2), there was a signifi cant increase from 2007 
to 2010 (APC, 4.0;  P  , .05). Th e AAPC in the PH death 
rate for 2001 to 2010 shows signifi cant increases for all 
races/ethnicities. Compared with NH whites, all race/
ethnicity trend lines were parallel but not coincident 
( P  , .05). 
 Death rates for PH were highest in the oldest age group 
(85 years and older) for every year ( Tables 7, 8 ) and 
increased by   65% between 2001 and 2010 (65.6 per 
100,000 to 108.7 per 100,000). PH death rates in the 
0- to 12-month age group were higher in 2001 (14.9 per 
100,000) than in 2010 (8.2 per 100,000). Th e PH death 
rate trend analysis by age group for 2001 to 2010 shows 
diff erences in the direction of the slope segments ( Fig 4 , 
 Table 9 ). Neonates through 12 months had the only sta-
tistically signifi cant decrease in rates (APC,  2 6.9; 
 P  , .05). Th e greatest increases in PH death rates were 
among the oldest age group (85 years and older) from 
 Figure 1 –  International Classifi cation of Diseases  coding for pulmo-
nary hypertension mortality: United States, 2001-2010 . I27.0  5 primary 
pulmonary hypertension; I27.2  5 other secondary pulmonary hyperten-
sion; I27.8  5 other specified pulmonary heart diseases; and I27.9  5 
pulmonary heart disease, unspecifi ed. Data are from the Multiple Cause 
of Death Files, 1999-2010, as compiled from data provided by the 
57 vital statistics jurisdictions through the Vital Statistics Cooperative 
Program. (Reprinted from the Centers for Disease Control and Preven-
tion, National Center for Health Statistics. 12 ) 
 Intercensal estimates of the US noninstitutionalized civilian population 
from 2001 to 2002 to 2009 to 2010 were provided by the US Bureau of 
the Census and were used to calculate age- and sex-specifi c hospitali-
zation rates per 100,000 people. Age-specifi c hospitalization rates were 
calculated for those aged  , 35 years, 35 to 44 years, 45 to 54 years, 55 
to 64 years, 65 to 74 years, 75 to 84 years, and   85 years. Hospitaliza-
tion rates were also directly age standardized to the 2000 US standard 
population using seven age groups. 16 Race-specifi c estimates are not 
provided because of incomplete reporting of race on hospital records. 
 In addition, the distribution of selected disease categories as the prin-
cipal (ie, fi rst listed) diagnosis was examined for each period among 
hospitalizations with any listed PH, and the average lengths of stay 
for PH-related hospitalizations were compared by age group. Average 
length of stay was estimated as the ratio of total days of care per dis-
charge to the total number of discharges. 
 A weighted least-squares regression method 17 was used to test for 
linear trends in hospitalization rates. A  P value of  , .05 indicated 
statistical signifi cance. Diff erences among subgroups were evaluated 
using unrounded numbers with two-tailed  t tests. Data analyses were 
performed using the statistical packages SAS, versions 9.2 and 9.3 
(SAS Institute Inc), and SUDAAN, versions 10.0 and 11.0 (Research 
Triangle Institute). 
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 TABLE 2  ]  ICD-CM Coding for Diagnosis During Hospitalizations and ICD for Mortality Used in the United 
States Since 2001 
ICD-CM Diagnoses During Hospitalizations ICD for Mortality
ICD-9-CM 2001 ICD-9-CM 2010 ICD-10-CM 2013 ICD-10 2001 ICD-10 2003
416. Pulmonary 
 heart disease
416. Pulmonary 
 heart disease
I27. Other pulmonary 
 heart diseases
I27. Other pulmonary 
 heart disease
I27. Other pulmonary 
 heart disease
416.0. Primary 
  pulmonary 
hypertension; 
idiopathic 
pulmonary 
arteriosclerosis; 
pulmonary 
hypertension 
(essential) 
(idiopathic) 
(primary)
416.0. Primary 
  pulmonary 
hypertension; 
idiopathic 
pulmonary 
arteriosclerosis; 
pulmonary 
hypertension 
(essential) 
(idiopathic) 
(primary)
I27.0. Primary 
  pulmonary 
hypertension
I27.0. Primary 
 pulmonary 
 hypertension
I27.0. Primary 
  pulmonary 
hypertension
416.1 Kyphoscoliotic 
 heart disease
416.1. Kyphoscoliotic 
 heart disease
I27.1. Kyphoscoliotic 
 heart disease
I27.1. Kyphoscoliotic 
 heart disease
I27.1. Kyphoscoliotic 
 heart disease
416.2. Chronic 
  pulmonary 
embolism
I27.2. Other 
  secondary 
pulmonary 
hypertension 
(pulmonary 
hypertension NOS )
I27.2. Other 
  secondary 
pulmonary 
hypertension
416.8. Other 
  specifi ed diseases 
of pulmonary 
circulation 
(pulmonary 
arteritis, 
endarteritis, 
rupture or 
stricture of 
pulmonary vessel
416.8. Other 
  specifi ed diseases 
of pulmonary 
circulation 
(pulmonary 
arteritis, 
endarteritis, 
rupture or stricture 
of pulmonary vessel
I27.8. Other 
  specifi ed 
pulmonary 
heart diseases
I27.8. Other 
  specifi ed pulmonary 
heart diseases
I27.8. Other 
  specifi ed 
pulmonary 
heart diseases
I27.81. Cor 
 pulmonale 
 (chronic)
I27.82. Chronic 
 pulmonary 
 embolism
I27.89. Other 
  specifi ed pulmonary 
heart diseases 
(Eisenmenger’s 
complex and 
syndrome)
417.9. Unspecifi ed 
  disease of 
pulmonary 
circulation
417.9. Unspecifi ed 
  disease of 
pulmonary 
circulation
I27.9. Pulmonary 
  heart disease, 
unspecifi ed 
(chronic 
cardiopulmonary 
disease)
I27.9. Pulmonary 
  heart disease, 
unspecifi ed
I27.9. Pulmonary 
  heart disease, 
unspecifi ed
 ICD  5  International Classiﬁ cation of Diseases ; ICD-9-CM  5  International Classiﬁ cation of Diseases, Ninth Revision, Clinical Modiﬁ cation ; 
ICD-10  5  International Classiﬁ cation of Diseases, Tenth Revision ; ICD-10-CM  5  International Classiﬁ cation of Diseases, Tenth Revision, 
Clinical Modiﬁ cation; NOS  5 not otherwise speciﬁ ed . 
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 TABLE 5  ]  Change in ASDRs (per 100,000) for Pulmonary Hypertension as Contributing Cause of Death 
Among Individuals of All Ages, by Sex: United States, 2001-2010 
Joinpoint Segment Sex APC AAPC (95% CI) (2001-2010)
2001-2006 All 0.6 1.9 b (1.5-2.4)
2006-2010 All 3.6 a …
2001-2006 Men  2 1.3 a 0.9 b (0.3-1.5)
2006-2010 Men 3.7 a …
2001-2006 Women 1.7 a 2.5 b (1.9-3.1)
2006-2010 Women 3.5 a …
 The National Vital Statistics System was used to ascertain deaths due to pulmonary hypertension, which were considered those with decedents having 
ICD-10 codes I27.0, I27.2, I27.8, or I27.9 reported as any contributing cause of death (ie, any of the possible 20 conditions, including the underlying 
cause of death). AAPCs are provided for the time period 2001 to 2010; the joinpoint varies and is based on the joinpoint regression analysis of best ﬁ t 
with the smallest number of deaths. Rates are per 100,000 population and are age standardized to the 2000 US standard population (eight age 
groups). AAPC  5 average annual percent change; APC  5 annual percent change. See  Table 2 and 3 legends for expansion of other abbreviations. 
 a APC is signiﬁ cantly diﬀ erent from zero at  a  5 0.05. 
 b AAPC is signiﬁ cantly diﬀ erent from zero at  a  5 0.05. 
 Figure 2 – Age-standardized death rates for pulmonary hypertension as 
a contributing cause of death and trend lines among individuals of all 
ages, by sex: United States, 2001-2010. Th e National Vital Statistics 
System was used to ascertain deaths due to pulmonary hypertension, 
which were considered those with decedents having  International 
Classifi cation of Diseases, 10th Revision (ICD-10) codes I27.0, I27.2, 
I27.8, or I27.9 reported as any contributing cause of death (ie, any of the 
possible 20 conditions, including the underlying cause of death). All trend 
lines are compared with the referent group, men;  P  , .05. Both par-
allelism and coincident comparison of trend lines were rejected. Rates are 
per 100,000 population and are age standardized to the 2000 US stan-
dard population (eight age groups). See  Table 5 for additional data. 
2001 to 2005 (APC, 3.9;  P  , .05) and from 2005 to 2010 
(APC, 7.2;  P  , .05). Th e AAPC for 2001 to 2010 shows 
signifi cant increases in PH death rates for those aged 
75 to 84 years and for those aged 85 years and older. 
Both parallelism and coincident comparisons of trend 
lines were rejected. 
 In 2001, the northern mountain states plus the District 
of Columbia, Vermont, New Hampshire, Delaware, 
North Carolina, and Ohio experienced the highest PH 
age-standardized death rates ( Fig 5 ). By 2010, several 
other western and midwestern states, including Iowa, 
Minnesota, Nebraska, Oregon, and Washington, had 
experienced signifi cant increases in death rates ( P  , .05) 
and had moved into the highest rate category. South 
Carolina and Tennessee also experienced signifi cant 
increases in death rates between 2001 and 2010 ( P  , .05). 
 In 2001, the most common UCOD among decedents 
with PH listed as any contributing cause of death was 
PH (29.3%), followed by chronic lower respiratory 
disease (26.2%), coronary heart disease (8.8%), and 
interstitial lung disease (4.5%) ( Table 10 ). Within the 
category of chronic lower respiratory disease, emphy-
sema was indicated in 4.2% of deaths ( Table 10 ). Th e 
most commonly reported underlying causes of death for 
all race/sex groups were PH and chronic lower respira-
tory disease. 
 In 2010, PH (at 30.2%) was the most common UCOD 
among decedents with PH listed as any cause of death, 
followed by chronic lower respiratory disease (19.0%), 
coronary heart disease (10.3%), and interstitial lung 
disease (4.9%) ( Table 11 ). Interestingly, from 2001 to 
2010, the percentage of PH deaths caused by emphy-
sema dropped from 4.2% to 1.4% of all PH deaths, 
whereas PH deaths caused by nonrheumatic valvular 
heart disease rose from 2.6% in 2001 to 4.1% in in 2010. 
Autoimmune diseases listed as the UCOD were higher 
for women than for men regardless of race or Hispanic 
origin. 
 Th e UCOD associated with PH showed several inter-
esting trends ( Table 12 ). Th e AAPC increased signifi -
cantly for several UCOD conditions, including coronary 
heart disease, aortic stenosis, hypertension, autoimmune 
disease, infl uenza, and pneumonia; it showed no signifi cant 
change for malignancies of the trachea and bronchus; 
 journal.publications.chestnet.org  483 
and it decreased for heart failure, chronic lower respira-
tory disease (emphysema in particular), and congenital 
malformations. 
 Hospitalizations 
 From 2001/2002 to 2009/2010, the age-adjusted rate of 
hospitalizations associated with PH increased by 44%, 
 Figure 3 – Age-standardized death rates for pulmonary hypertension as 
a contributing cause of death and trend lines among individuals of all 
ages, by race/ethnicity: United States, 2001-2010. Th e National Vital 
Statistics System was used to ascertain deaths due to pulmonary hyper-
tension, which were considered those with decedents having ICD-10 
codes I27.0, I27.2, I27.8, or I27.9 reported as any contributing cause of 
death (ie, any of the possible 20 conditions, including the underlying 
cause of death).  a Rates are per 100,000 population and are age standard-
ized to the 2000 US standard population (eight age groups);  b all race/
ethnicity trend lines are parallel to the referent group of NHW,  P  , .05. 
Th ere are no statistically signifi cant coincident trend lines to the referent 
group of NHW. See  Table 6 for additional data. NHAIAN  5 non-
Hispanic American Indian/Alaska native; NHAPI  5 non-Hispanic 
Asian/Pacifi c Islander; NHB  5 non-Hispanic black; NHW  5 non-Hispanic 
white. See  Figure 2 legend for expansion of other abbreviation. 
 TABLE 6  ]  Change in ASDRs for Pulmonary 
Hypertension as Contributing Cause of 
Death Among Individuals of All Ages, by 
Race/Ethnicity: United States, 2001-2010 
Joinpoint 
Segment Race/Ethnicity APC
AAPC (95% CI) 
(2001-2010)
2001-2006 NH white 0.5 1.9 a (1.5-2.4)
2006-2010 NH white 3.8 b 
2001-2010 NH black 2.3 b 2.3 a (1.9-2.8)
2001-2010 NH AI or AN 4.0 b 4.0 a (1.6-6.4)
2001-2010 NH API 3.7 b 3.7 a (1.9-5.5)
2001-2007 Hispanic 0.2 1.5 a (0.8-2.2)
2007-2010 Hispanic 4.0 b 
 The National Vital Statistics System was used to ascertain deaths due to 
pulmonary hypertension, which were considered those with decedents 
having ICD-10 codes I27.0, I27.2, I27.8, or I27.9 reported as any 
contributing cause of death (ie, any of the possible 20 conditions, 
including the underlying cause of death). See  Table 2, 3 , and  5 legends 
for expansion of abbreviations. 
 a AAPC is signiﬁ cantly diﬀ erent from zero at  a  5 0.05. 
 b APC is signiﬁ cantly diﬀ erent from zero at  a  5 0.05.   TA
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from 91 per 100,000 discharges to 131 per 100,000 dis-
charges ( P  , .001). Th e rate of hospitalization for 
women increased by 52%, from 97 per 100,000 to 
147 per 100,000 ( P  , .001). Th e rate of hospitalization 
for men increased by 33%, from 83 per 100,000 to 
110 per 100,000 ( P  , .01). Crude and age-adjusted hos-
pitalization rates were both higher for women than for 
men at each time interval, except for 2007 to 2008 
( P  , .05) ( Table 13 ). Th e proportion of total PH hospi-
talizations among women remained consistently higher 
than among men: Women accounted for 61% of all 
PH hospitalizations in 2001/2002 and 63% in 
2009/2010 ( Table 14 ). 
 Rates of PH hospitalization increased over the time 
period for those aged  , 35 years, 45 to 54 years, 75 to 
84 years, and   85 years ( Table 13 ). Th ere was no signif-
icant change in hospitalization rates for those aged 35 to 
44 years, 55 to 64 years, or 75 to 84 years. Th e rate of 
PH hospitalization for those aged   85 years had the 
greatest increase, rising by 83%, from 834 per 100,000 to 
1,527 per 100,000 ( P  , .001). Th e 75- to 84-year-old age 
group had the highest proportion of hospitalizations of 
all age groups throughout the period (27% in 2001-2002 
and in 2009-2010) ( Table 14 ). Among men, the only sig-
nifi cant increase in the PH hospitalization rate from 2001 
to 2002 to 2009 to 2010 was for those aged   85 years   TA
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 Figure 4 – Age-specifi c death rates for pulmonary hypertension as a 
contributing cause of death and trend lines among individuals of all ages, 
by six age groups: United States, 2001-2010. Th e National Vital Statistics 
System was used to ascertain deaths due to pulmonary hypertension, 
which were considered those with decedents having ICD-10 codes I27.0, 
I27.2, I27.8, or I27.9 reported as any contributing cause of death (ie, any 
of the possible 20 conditions, including the underlying cause of death). 
 a Rates are per 100,000 population and age-specifi c death rates were cal-
culated for each of six age groups;  b all age-specifi c trend lines are com-
pared with the referent age group of 0 to 12 mo,  P  , .05. Both parallelism 
and coincident comparison of trend lines were rejected. See  Table 9 for 
additional data. See  Figure 2 legend for expansion of abbreviation. 
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(606 in 2001 to 1,173 in 2010;  P  , .01) ( Table 13 ). 
Among women, the rate of hospitalization increased 
for almost all age groups ( , 35 years, 45-54 years, 
75-84 years, and   85 years) ( Table 13 ). Th e hospitaliza-
tion rate for women  , 35 years old was the lowest 
among all women and had the greatest percentage 
increase over time. For both men and women, rates of 
hospitalization increased as age increased. Hospitaliza-
tions of those   85 years old were predominately among 
women from 2001 to 2002 through 2009 to 2010; in fact, 
in 2009 to 2010, 75% of hospitalizations in this age 
group were of women ( Table 14 ). 
 Th e three most commonly reported principal diagnoses 
at inpatient discharges with any listed PH remained the 
same throughout the 10-year period ( Table 15 ). Th e 
most common principal diagnosis was congestive heart 
failure, followed by other heart diseases (which included 
PH) and chronic and unspecifi ed bronchitis. Congestive 
heart failure was the primary diagnosis for 19% of the 
PH hospitalizations in 2001 to 2002 and for 18% in 2009 
to 2010. Th e top three diagnoses accounted for 43% of 
the hospitalizations in 2001 to 2002 and for 37% in 2009 
to 2010. Pneumonia and cardiac dysrhythmias rounded 
out the fi ve leading principal diagnoses, except in 2007 
to 2008, when respiratory failure was the fi ft h most 
common principal diagnosis. Acute myocardial infarc-
tion moved from the sixth most frequent principal diag-
nosis in 2001 to 2002 to the 10th most frequent in 2009 
to 2010. Nephritis, nephrotic syndrome, and nephrosis 
fi rst appeared as the 10th most common primary diag-
nosis in 2007 to 2008 and moved up to the seventh most 
common primary diagnosis in 2009 to 2010. 
 Th ere were no signifi cant trends in the average length of 
stay or the discharge status for any age group or for men 
or women from 2001 to 2002 to 2009 to 2010 ( Fig 6 ). 
However, in 2001 to 2002, and again in 2009 to 2010, 
the average length of stay for hospitalizations for those 
aged  , 35 years was signifi cantly longer than for any 
other age group. In 2009 to 2010, signifi cantly more 
men than women were discharged home ( P  , .02), and 
signifi cantly more women than men were discharged to 
long-term care ( P  , .001) ( Fig 7 ). As age increased, the 
percentage discharged to home decreased. 
 Discussion 
 Th e fi ndings in our report indicate signifi cant increases 
in death rates associated with PH for women, men, all 
racial/ethnic groups, and especially among those aged 
75 years and older. Considering all PH deaths from 
2001 to 2010, we identifi ed signifi cant decreases from 
PH associated with chronic lower respiratory disease 
(including emphysema specifi cally), conditions arising 
in the perinatal period, congenital malformations, and 
pulmonary embolism. At the same time, we identifi ed 
increases from 2001 to 2010 in death rates for PH asso-
ciated with aortic stenosis, hypertension, coronary heart 
disease, autoimmune diseases, diabetes, renal disease, 
and chronic liver disease. Given that PH mortality due 
to chronic lower respiratory disease represents a signifi -
cant proportion of total PH mortality, the decline from 
 TABLE 9  ]  Death and Age-Specifi c Death Rates for Pulmonary Hypertension as Contributing Cause of Death 
Among Individuals of All Ages, by Six Age Groups: United States, 2001-2010 
Joinpoint Segment Age Group, y APC 2001-2010 AAPC (95% CI)
2001-2010 0-12 a  2 6.9 b  2 6.9 c ( 2 11.1 to  2 2.5)
2001-2010 1-54 0.1 0.1 ( 2 0.6 to 0.7)
2001-2010 55-64  2 0.2  2 0.2 ( 2 0.6 to 0.2)
2001-2007 65-74  2 0.9 0.1 ( 2 0.7 to 0.9)
2007-2010 65-74 2.0 …
2001-2004 75-84 0.1 2.5 c (1.6 to 3.4)
2004-2010 75-84 3.7 b …
2001-2005 85 1 3.9 b 5.7 c (5.3 to 6.2)
2005-2010 85 1 7.2 b …
 The National Vital Statistics System was used to ascertain deaths due to pulmonary hypertension, which were considered those with decedents having 
ICD-10 codes I27.0, I27.2, I27.8, or I27.9 reported as any contributing cause of death (ie, any of the possible 20 conditions, including the underlying 
cause of death). Rates are per 100,000 population and age-speciﬁ c death rates were calculated for each of six age groups. See  Table 2 and  5 legends 
for expansion of abbreviations. 
 a Mo. 
 b APC is signiﬁ cantly diﬀ erent from zero at  a  5 0.05. 
 c AAPC is signiﬁ cantly diﬀ erent from zero at  a  5 0.05. 
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 Figure 5 – Age-standardized death rates for pulmonary hypertension as 
any cause of death among all ages by state. A, Death rates in 2001. B, 
Death rates in 2010 . Th e National Vital Statistics System was used to 
ascertain deaths due to pulmonary hypertension, which were considered 
those with decedents having ICD-10 codes I27.0, I27.2, I27.8, or I27.9 
reported as any contributing cause of death (ie, any of the possible 20 con-
ditions, including the underlying cause of death). Rates are per 100,000 
population and are age standardized to the 2000 US standard population 
(eight age groups). See  Figure 2 legend for expansion of abbreviation. 
2001 to 2010 in these death rates may be aff ecting the 
increasing rates identifi ed with other PH-associated 
conditions; therefore, the signifi cant rates associated 
with other conditions such as aortic stenosis, hyperten-
sion, diabetes, renal disease, and chronic liver disease 
should be interpreted with caution, given their individ-
ually smaller contributions to total PH mortality. 
 Death rates among those   85 years old have increased 
rapidly since 2001. Th e Registry to Evaluate Early and 
Long-term PAH Disease Management (REVEAL Reg-
istry) compared demographics from their data on 
patients with group 1 PAH with those from a National 
Institutes of Health (NIH) registry from 1982. Th ey 
found that their current registry patients had a mean 
age of 45 years compared with 36 years in the NIH reg-
istry in 1982, and a higher prevalence of women (78% 
vs 63%). 18 
 Diff erences in death rates by sex and race/ethnicity 
were reported previously, 2,19,20 and this report adds 
important new information about those trends. A pre-
vious report 2 showed that the trend in the PH mor-
tality rate for men actually declined from 1980 through 
2002; information in this report shows that the rates 
for men continued to decline until 2006 and then 
began increasing. In general, between 2001 and 2010, 
mortality rates from COPD declined among men 12 and 
this may explain, in part, the long-term decline in 
mortality among men with PH that was trending from 
1980 to 2006. Reasons for the reversal in trend for men 
are unclear, but the previous decline may have been 
associated with reductions in COPD and emphysema, 
which the current analysis identifi es as well. On the 
other hand, we identifi ed increases in the rates of PH 
mortality in association with coronary heart disease 
and hypertension as well as autoimmune disease in 
men. Few studies have found male sex to be a risk 
factor for death among patients with PH associated 
with autoimmune disease. 21 
 Death rates associated with PH for women from 2001 
to 2010 were consistently higher than those for men. 
Th ese sex diff erences are consistent with data from the 
REVEAL Registry, in which the patients were more 
likely to be women. 18 Women have higher rates of con-
nective tissue disease than do men. 22 Th e French 
National Pulmonary Hypertension registry found that 
women have higher rates of idiopathic and inherited 
PH compared with men. 23 In the REVEAL Registry, 
which includes only patients with PAH, it was found 
that roughly one-half of patients with PAH had idio-
pathic PAH and one-half had associated PAH, with 
connective tissue disease accounting for roughly 25% 
of the patients in the registry. 24 With current ICD-10 
mortality codes, there are challenges in separating 
PAH as idiopathic vs associated ( Fig 1 ,  Table 2 ). 
Indeed, most causes of death from PH in the multiple 
cause of death fi les are listed as “other secondary PH” 
or “PH, not otherwise specifi ed.” Few cases are listed 
as “primary PH.” In a retrospective cohort study of 
55 patients with PAH, Kawut et al 25 found that patients 
with systemic sclerosis associated with PH had a 
higher risk of death despite having similar demo-
graphic and hemodynamic characteristics. Research is 
also ongoing regarding a hormonal mechanism that 
may explain the sex diff erences. 9,26 Diff erential sex 
exposure to anorexigens may also help explain some 
 journal.publications.chestnet.org  487 
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sex diff erences, 18 although it is unclear to what extent 
this applies to the US population. 
 Mortality rates for blacks are increasing at a greater rate 
than they are for whites. Th e race/sex diff erences found 
in these data are consistent with data from the REVEAL 
Registry, which noted that the greatest ratios of female 
to male patients in the registry by race/ethnicity were 
among blacks and the lowest were among whites. 18 In 
addition to increased connective tissue disease among 
black women , blacks in general have higher rates of 
connective tissue disease, hypertension, and hemoglo-
binopathies in association with PH than do whites. 22 
 Mortality data for all decedents with PH listed on the 
death certifi cate are consistent with a widening race/sex 
gap in recent years, although age-adjusted race/sex mor-
tality gaps are less prominent than are patient ratios in 
the REVEAL Registry, which is not age adjusted and 
only includes PAH. Diff erential race/ethnicity changes 
 TABLE 12  ]  Trends Over Time by Underlying Cause of Death Among Decedents With Reported PH 
Disease Category: ICD-10 Codes
 2001 2010
AAPCRate/100,000
% of Total PH 
Deaths Rate/100,000
% of Total 
PH Deaths
Diseases of the circulatory system
 Pulmonary hypertension: I27.0, I27.2, 
   I27.8, I27.9
1.63 29.3 1.95 30.2 1.5
 Coronary heart disease: I20-I25 0.48 8.8 0.66 10.3 3.8 a 
 Valvular heart disease, nonrheumatic: I34-I38 0.14 2.6 0.25 4.1 6.7 a 
 Aortic stenosis: I06.0, I35.0, I35.2 0.04 0.9 0.10 1.6 10.8 a 
 Hypertension: I10-I15 0.04 1.0 0.10 1.6 9.2 a 
 Rheumatic heart disease: I00-I09 0.07 1.4 0.10 1.5 3.2 a 
 Pulmonary embolism: I26 0.07 1.3 0.04 0.7  2 7.2 a 
 Heart failure: I50 0.03 0.6 0.02 0.4  2 3.6 a 
 Other cardiovascular/cerebrovascular 
   disease: I27.1, I28-I33, I40-I49, I51-I78
0.21 3.6 0.23 3.7 2.0
Respiratory disorder or infection
 Chronic lower respiratory disease: J40-J47 1.46 26.2 1.24 19.0  2 1.3 a 
  Emphysema only: J43 0.24 4.2 0.08 1.4  2 8.7 a 
 Interstitial lung disease: J84 0.24 4.5 0.31 4.9 4.5 a 
 Infl uenza and pneumonia: J09-J18 0.04 0.9 0.07 1.2 5.5 a 
All other respiratory diseases: J00-06, J20-J39, 
   J60-J70, J85-J98
0.08 1.7 0.12 1.9 3.3 a 
Autoimmune diseases: M5-M6, M8, M30-35 0.07 1.3 0.16 2.4 10.9 a 
Congenital malformations, deformation, and 
   chromosomal abnormalities: Q00-Q99
0.17 3.0 0.11 1.6  2 5.2 a 
Malignant neoplasms of the trachea, bronchus, 
   and lung: C34
0.09 1.8 0.09 1.5 0.1
Diabetes mellitus: E10-E14 0.05 1.0 0.09 1.5 7.6 a 
Nephritis, nephrotic syndrome, and nephrosis: 
   N00-N07, N17-N19, N25-N27
0.03 0.7 0.07 1.1 9.2 a 
Chronic liver disease and cirrhosis: K70, K73-74 0.02 0.3 0.05 0.8 17.0 a 
Malignant neoplasms of lymphoid, hematopoietic, 
   and related tissue: C81-C96
0.02 0.4 0.04 0.7 6.4 a 
Sleep apnea: G47.3 … 0.1 0.04 0.6 NA
Certain conditions originating in the perinatal 
   period: P00-P96
0.05 1.0 0.01 0.1  2 12.5 a 
Total 5.5 … 6.5 … …
 NA  5 not applicable; PH  5 pulmonary hypertension. See  Table 2 and  5 legends for expansion of other abbreviations . 
 a P  , .05. 
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 TABLE 13  ]  Hospitalization Rates (per 100,000) With Any Listed Pulmonary Hypertension Diagnosis by Age 
and Sex: United States, 2001/2002 Through 2009/2010 
Sex and Age Groups 2001/2002 2003/2004 2005/2006 2007/2008 2009/2010
Age-standardized a 
   rate
 Total 91 (85-97) 87 (81-93) 94 (88-100) 112 (100-124) 131 (115-147)
  Female 97 (89-105) 93 (85-101) 100 (92-108) 115 (101-129) 147 (129-165)
  Male 83 (75-91) 80 (70-90) 85 (77-93) 108 (94-122) 110 (92-128)
Age-specifi c rate
 Total 91 (82-101) 89 (78-99) 96 (85-108) 117 (95-140) 140 (106-173)
   , 35 y 7 (6-9) 10 (7-12) 11 (8-14) 10 (7-13) 17 b 
  35-44 y 35 (25-46) 27 (21-33) 40 (31-49) 40 (25-54) 38 (24-52)
  45-54 y 58 (48-69) 69 (52-87) 68 (55-82) 85 (63-107) 85 (61-110)
  55-64 y 178 (151-206) 158 (130-187) 137 (111-163) 154 (114-194) 166 (122-210)
  65-74 y 314 (271-357) 303 (259-348) 297 (246-348) 383 (301-465) 418 (308-529)
  75-84 y 553 (478-629) 529 (444-614) 606 (521-691) 711 (552-869) 872 (658-1,086)
    85 y 834 (647-1,020) 728 (559-897) 890 (746-1,035) 1,182 (896-1,468) 1,527 (1,158-1,896)
 Female 109 (96-122) 104 (92-117) 115 (100-129) 134 (108-161) 175 (133-216)
   , 35 y 8 (6-11) 9 (6-11) 14 (9-19) 11 (7-15) 19 (9-28)
  35-44 y 38 (19-57) 34 (25-43) 41 (29-54) 42 (24-59) 42 (25-60)
  45-54 y 62 (47-78) 73 (55-91) 72 (55-89) 92 (64-120) 108 (71-146)
  55-64 y 203 (160-246) 160 (120-199) 141 (113-169) 142 (110-175) 173 (118-228)
  65-74 y 334 (275-394) 309 (259-360) 329 (259-400) 405 (302-508) 458 (329-587)
  75-84 y 545 (464-626) 589 (491-686) 620 (526-713) 710 (530-891) 986 (726-1,247)
    85 y 931 (704-1,159) 787 (581-992) 967 (789-1,144) 1,223 (915-1,531) 1,697 (1,290-2,104)
 Male 73 (65-82) 72 (61-83) 77 (67-88) 100 (79-121) 104 (77-131)
   , 35 y 7 (4-9) 11 (8-14) 8 (5-12) 9 (5-12) 16 b 
  35-44 y 33 (22-43) 20 (13-27) 38 (23-53) 38 (16-60) 33 (16-50)
  45-54 y 54 (41-67) 65 (43-88) 64 (45-82) 77 (51-104) 62 (41-82)
  55-64 y 151 (116-187) 157 (117-196) 134 (102-165) 167 (104-229) 159 (110-208)
  65-74 y 290 (234-346) 296 (233-358) 259 (210-308) 357 (277-438) 373 (260-486)
  75-84 y 566 (460-672) 440 (312-569) 586 (467-705) 711 (539-884) 713 (505-921)
    85 y 606 (425-787) 595 (406-785) 725 (531-920) 1,095 (707-1,483) 1,173 (794-1,551)
 Data are presented as rate (95% CI). (Adapted with permission from Centers for Disease Control and Prevention, National Center for Health 
Statistics. 11 ) 
 a To the 2000 US standard population. 
 b Estimate does not meet standards of reliability or precision. The National Center for Health Statistics considers an estimate to be reliable if it is 
based on at least 30 discharge records and it has a relative SE of   30% (ie, the SE is   30% of the estimate). 
over time may also be related to changing population 
demographics for PH mortality over the past decades. 
Previous studies have reported that blacks have a shorter 
survival from the time of diagnosis of PH, 27 and have 
higher rates of PH associated with connective tissue 
disease. Our fi ndings of increasing rates of PH mortality 
associated with hypertension, diabetes, and renal failure 
may also contribute to the racial gap in PH mortality. 
Poms et al 28 found that those with PAH and diabetes 
have decreased survival. 
 Although they did not report on race/ethnicity associa-
tions of PH with chronic kidney disease, Bolignano 
et al 29 suggested that renal failure itself may be a trigger 
for PH. Overall mortality from diabetes (listed as the 
UCOD) declined from 2001 to 2010, 30 whereas deaths 
from diabetes in patients with PH have increased. 
 Interestingly, the geographic pattern of PH death rates 
by state does not mirror the patterns seen in maps 
showing all heart disease deaths, where the highest rates 
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 TABLE 15  ]  Primary Diagnoses for Hospitalizations with Any Listed Pulmonary Hypertension Diagnosis: United 
States, 2001/2002 Through 2009/2010 
Primary Diagnosis (ICD-9-CM Diagnosis Codes) 2001/2002 2003/2004 2005/2006 2007/2008 2009/2010
Congestive heart failure: 428.0,428.2-428.4 19.2 19.9 19.5 17.0 17.6
Other heart disease (includes pulmonary 
 hypertension): 391.0-392.0, 393-398, 415-416, 
 420-426, 428.1, 428.9-429.9
12.7 16.0 13.1 12.9 12.0
Chronic and unspecifi ed bronchitis: 490-491 10.6 7.8 9.2 6.9 7.3
Pneumonia: 480-486 7.3 6.3 5.9 4.4 6.2
Cardiac dysrhythmias: 427 4.3 4.8 5.9 5.8 5.1
Acute myocardial infarction: 410 3.9 3.0 2.4 3.4 2.3
Respiratory failure: 518.81, 518.83, 518.84 3.5 3.8 4.2 4.7 4.3
Coronary atherosclerosis: 414.0, 414.2, 414.3 3.4 4.1 3.4 3.3 2.5
Other diseases of the respiratory system: 416.2, 
 471-472, 475-478, 487, 488.0, 488.1, 
 500-511.1, 511.8-518.6, 518.82, 518.89-519
2.8 2.9 2.1 2.5 2.1
Hypertensive heart disease: 402, 404 2.3 1.6 1.2 0.7 1.5
Other COPD and allied conditions: 492, 494-496 1.8 2.1 0.9 0.3 0.5
Cerebrovascular disease: 430-438 1.3 1.3 2.0 1.8 2.1
Nephritis, nephrotic syndrome, and nephrosis: 
 580-589
0.6 0.8 0.8 2.3 2.7
Asthma: 493 1.4 1.6 1.9 1.1 2.4
Anemias: 280-285 1.0 1.5 1.8 0.9 1.6
Complications of medical and surgical care, not 
 elsewhere classifi ed: 996-999
1.2 1.5 1.5 1.4 1.6
Other diseases of the circulatory system: 390, 
 392.9, 403, 405, 417, 451-454, 456-459
0.7 1.4 1.5 1.5 1.9
All other diagnoses 21.8 19.8 22.6 29.2 26.6
 Data are presented as %. See  Table 2 legend for expansion of abbreviation. (Adapted with permission from Centers for Disease Control and Preven-
tion, National Center for Health Statistics. 11 ) 
are typically located in the deep south and the lowest 
rates in the northwest. 31 Th is highlights the diff erences 
in risk factors and populations at risk of PH. 
 We also found increasing hospitalization rates for both 
men and women, and there has been some shift  in the 
most common primary reason for admission. Although 
heart failure is the most common underlying reason for 
admission associated with PH, the proportion of hospi-
talizations for heart failure associated with PH has 
declined, as have most major reasons for hospitalization 
associated with PH. Yet hospitalizations for asthma, 
renal conditions, and the category of less common con-
ditions associated with PH have increased. Th is may 
refl ect better documentation, but it may also suggest 
important changes in the underlying conditions associ-
ated with PH. 
 Th e fact that we found that women have twice as many 
hospitalizations associated with PH than do men likely 
refl ects the diff erence in life expectancy but also the dis-
proportionate burden of PH disease experienced by 
women. Compared with the previous report covering 
1980 to 2002, women continue to have higher rates of 
hospitalizations than do men, and the greatest increase 
in rates over time is in the oldest age group. For women, 
increases in the PH hospitalization rate were noted 
across most age groups, whereas for men, the rate 
increased only among those   85 years old. Most hospi-
talizations for those   85 years old were among women. 
Discharge status is likely infl uenced by these demo-
graphic differences, with more women discharged 
to long-term care and more men discharged to their 
home. 
 Although some of the increase in mortality from PH-
associated conditions may be explained by a heightened 
awareness of PH and referral to specialists able to make 
the diagnosis, the signifi cant declines in mortality from 
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 Figure 6 – Comparison of average length of hospital stay by age groups 
for discharges for pulmonary hypertension (PH) as any listed Interna-
tional Classifi cation of Diseases, Ninth Revision, Clinical Modifi cation 
(ICD-9-CM) diagnosis: United States, 2001/2002 and 2009/2010. In 
both 2001/2002 and 2009/2010, the average length of stay for PH hospi-
talizations for those aged   35 y was longer than for all other age groups 
( P  , .05). (Adapted with permission from Centers for Disease Control and 
Prevention, National Center for Health Statistics. 11 ) 
  
 Figure 7 – Hospital discharge status by sex for pulmonary hypertension 
as any listed ICD-9-CM diagnosis: United States, 2009/2010. In 
2009/2010, more men than women were discharged home ( P  , .03), and 
more women than men were discharged to LTC ( P  , .01). LTC  5 long-
term care; STC  5 short-term care. See  Figure 6 legend for expansion of 
other abbreviation. (Adapted with permission from Centers for Disease 
Control and Prevention, National Center for Health Statistics. 11 ) 
congenital malformations, and conditions originating in 
the perinatal period, may be explained in part by both 
increased awareness and improved treatment. Although 
there has been a signifi cant increase in the overall mor-
tality rate for PH since 1980, it is interesting to note that 
the REVEAL Registry found similar severity at diagnosis 
(as evidenced by New York Heart Association and 
World Health Organization functional classes) between 
the NIH registry and the REVEAL Registry for PAH, 
and yet one in fi ve patients diagnosed with PAH pre-
sented with a history of having symptoms for  . 2 years 
prior to diagnosis. 3 In the United Kingdom and Ireland 
cohort study from 2001 to 2009, patients were still pre-
senting with severe symptoms late in the course of 
disease. 32 Given the accelerating rate of mortality among 
those aged   85 years, the overall increase in mortality 
from PH may refl ect diff erent characteristics of disease 
manifestation among the older patients with additional 
comorbid conditions. Canadian researchers found that 
patients   65 years old were more likely to have PH 
associated with scleroderma than were younger patients, 
although they also noted that younger patients with PH 
associated with scleroderma were more likely to die 
during a median follow-up of 3 years. 33 
 Th is report is subject to several limitations related to 
both mortality and hospitalization data. First, death cer-
tifi cates may not accurately capture the UCOD or con-
tributing causes of death because of inaccuracy of 
diagnosis or limited knowledge of the deceased’s med-
ical history by the person completing the death certifi -
cate. Th is limitation may result in underreporting of PH 
on death certifi cates. Second, race and ethnicity may not 
be accurately captured on death certifi cates or hospitali-
zation data, especially for Hispanics and races other 
than black or white. Th is may aff ect the observed mor-
tality and hospitalization rates for Hispanics and other 
nonwhite/nonblack individuals, especially AI/AN dece-
dents. 14 Th ird, comparisons of mortality data with epi-
demiologic data from disease registries are limited by 
the fact that some disease registries are prevalence regis-
tries, whereas others are incident registries, or they sep-
arate incident and prevalent cases, and by the fact that 
disease registries are predominately for PAH rather than 
for all PH causes. Fourth, although trends in UCOD 
over time can be identifi ed, secular changes in the inci-
dence or prevalence of the diseases reported as the 
UCOD over time are not refl ected in the mortality 
trends shown here. Th erefore, these trends must be 
interpreted with caution. Fift h, the NHDS does not 
include patients admitted to federal, military or Vet-
erans Aff airs hospitals; therefore, results underestimate 
the total number of hospitalizations for PH among 
adults. Sixth, unfortunately, the terminology used in the 
ICD and ICD-CM does not crosswalk easily with the 
Dana Point classifi cation of PH, and although using 
the identical fourth digits in both the ICD-9-CM and 
the ICD-10, the descriptions do not crosswalk well with 
each other, nor do they crosswalk well with the Dana 
Point PH classifi cation of PH. Th is contributes to chal-
lenges in correct classifi cation of causes of death and 
hospital diagnoses. Lastly, the NHDS increased the 
number of diagnoses collected in 2010 from seven to 15. 
Th e number of diagnoses collected has a signifi cant 
impact on estimates, particularly for conditions that are 
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 TABLE 16  ]  Difference in Hospital Discharges for Pulmonary Hypertension as Any Listed ICD-9-CM Diagnosis 
Using Seven vs 15 Diagnoses by Age Group: United States, 2010 
Age Groups
Pulmonary Hypertension 
Discharges 2010 (Seven Diagnoses)
Pulmonary Hypertension 
Discharges 2010 (15 Diagnoses) Percent Diﬀ erence
Total 472 729 54
  , 35 y 27 a 30 a 10
 35-44 y 19 25 33
 45-54 y 41 58 43
 55-64 y 61 93 52
 65-74 y 99 155 57
 75-84 y 130 210 62
   85 y 96 158 66
 Numbers are presented in thousands. See  Table 2 legend for expansion of abbreviations. (Adapted with permission from Centers for Disease Control 
and Prevention, National Center for Health Statistics. 11 ) 
 a Estimate does not meet standards of reliability or precision. The National Center for Health Statistics considers an estimate to be reliable if it is 
based on at least 30 discharge records and it has a relative SE of   30% (ie, the SE is   30% of the estimate). 
typically secondary diagnoses such as PH. Larger per-
centage diff erences can be seen in hospitalizations for 
older people, who are more likely to carry multiple diag-
noses. Th e estimated number of PH hospitalizations in 
2010 using seven diagnoses was 471,864, but the esti-
mate increased to 728, 983 when using 15 diagnoses 
(a 54% increase in the estimated number of hospitaliza-
tions [ Table 16 ]). For those aged 85 years and older, 
there is a 66% increase in the estimated number of hos-
pitalizations if 15 diagnoses are used, compared with 
seven diagnoses. Th is analysis helps explain diff erences 
in previously reported hospitalizations associated with 
PH from the Healthcare Cost and Utilization Project 
on hospital stays related to PH. 34 
 Conclusions 
 Our report documents increases in mortality associated 
with PH among men, women, and all race and ethnic 
groups, and from several conditions commonly associ-
ated with PH (hypertension and coronary heart disease, 
aortic stenosis, liver disease and cirrhosis, and autoim-
mune disease) but also from renal disease and diabetes, 
while fi nding that PH-associated mortality decreased 
over time from deaths due to congenital malformations 
among newborns, and for emphysema, chronic lower 
respiratory disease, and pulmonary embolism. Approxi-
mately one-half of deaths associated with PH occur 
among those under 75 years of age. Although PH death 
rates have been stable for those aged 1 to 74 years over 
the past decade, the identifi ed increases in PH death 
among those with a UCOD from hypertension, coro-
nary heart disease, and valvular disease may be avoid-
able with improved public health eff orts in the primary 
prevention of heart disease. Th e increased mortality 
from autoimmune conditions in association with PH 
requires further study. Increases in hospitalizations may 
refl ect both improved recognition of PH as well as an 
increase in treatment options. Th e decline in PH mor-
tality due to congenital malformations, chronic lower 
respiratory disease, and emphysema over time is 
encouraging. Th e ability to code mortality and hospitali-
zations using a modifi ed diagnostic classifi cation based 
on the fi ve major classes in the Dana Point classifi cation 
could improve the surveillance of PH, which would also 
aid in understanding age, race, and sex diff erences in 
PH mortality. 
 Acknowledgments 
 Financial/nonfinancial disclosures: The authors have reported to 
 CHEST that no potential conflicts of interest exist with any com-
panies/organizations whose products or services may be discussed 
in this article. The findings and conclusions in this article are those 
of the authors and do not necessarily represent the official position 
of the US Centers for Disease Control and Prevention . 
 References 
  1 .  Aronson  JK .  Rare diseases and orphan drugs .  Br J Clin Pharmacol . 
 2006 ; 61 ( 3 ): 243 - 245 .  
  2 .  Hyduk  A ,  Croft   JB ,  Ayala  C ,  Zheng  K ,  Zheng  ZJ ,  Mensah  GA . 
 Pulmonary hypertension surveillance—United States, 1980-2002 . 
 MMWR Surveill Summ .  2005 ; 54 ( 5 ): 1 - 28 . 
  3 .  Brown  LM ,  Chen  H ,  Halpern  S ,  et al .  Delay in recognition of pul-
monary arterial hypertension: factors identifi ed from the REVEAL 
Registry .  Chest .  2011 ; 140 ( 1 ): 19 - 26 .  
  4 .  Deaño  RC ,  Glassner-Kolmin  C ,  Rubenfi re  M ,  et al .  Referral of 
patients with pulmonary hypertension diagnoses to tertiary pulmo-
nary hypertension centers: the multicenter RePHerral study .  JAMA 
Intern Med .  2013 ; 173 ( 10 ): 887 - 893 .  
  5 .  Badesch  DB ,  Champion  HC ,  Sanchez  MAG ,  et al .  Diagnosis and 
assessment of pulmonary arterial hypertension .  J Am Coll Cardiol . 
 2009 ; 54 ( suppl 1 ): S55 - S66 .  
 journal.publications.chestnet.org  495 
  6 .  Simonneau  G ,  Robbins  IM ,  Beghetti  M ,  et al .  Updated clinical 
classifi cation of pulmonary hypertension .  J Am Coll Cardiol .  2009 ;
 54 ( suppl 1 ): S43 - S54 .  
  7 .  Th enappan  T ,  Ryan  JJ ,  Archer  SL .  Evolving epidemiology of 
pulmonary arterial hypertension .  Am J Respir Crit Care Med . 
 2012 ; 186 ( 8 ): 707 - 709 .  
  8 .  Humbert  M ,  Simonneau  G ,  Rubin  LJ .  A decade of achievement 
in pulmonary hypertension .  Eur Respir Rev .  2011 ; 20 ( 122 ):
 215 - 217 .  
  9 .  Peacock  A .  Pulmonary hypertension .  Eur Respir Rev .  2013 ; 22 ( 127 ):
 20 - 25 .  
  10 .  McGoon  MD ,  Krichman  A ,  Farber  HW ,  et al .  Design of the 
REVEAL registry for US patients with pulmonary arterial hyperten-
sion .  Mayo Clin Proc .  2008 ; 83 ( 8 ): 923 - 931 . 
  11 . Centers for Disease Control and Prevention, National Center for 
Health Statistics. National Hospital Discharge Survey. Centers for 
Disease Control and Prevention website.  http://www.cdc.gov/nchs/
nhds.htm. Accessed March 31,  2014. 
  12 .  Centers for Disease Control and Prevention, National Center for 
Health Statistics . About underlying cause of death 1999-2010. 
CDC WONDER website.  http://wonder.cdc.gov/ucd-icd10.html. 
Accessed December 22,  2013. 
  13 .  Link  J ,  Glazer  C ,  Torres  F ,  Chin  K .  International Classifi cation 
of Diseases coding changes lead to profound declines in reported 
idiopathic pulmonary arterial hypertension mortality and hospitali-
zations: implications for database studies .  Chest .  2011 ; 139 ( 3 ):
 497 - 504 .  
  14 .  Arias  E ,  Schauman  WS ,  Eschbach  K ,  Sorlie  PD ,  Backlund  E . Th e 
validity of race and Hispanic origin reporting on death certifi cates 
in the United States.  Vital Health Stat 2 .  2008 ; (148):1-13. 
  15 .  Hall  MJ ,  DeFrances  CJ ,  Williams  SN ,  Golosinskiy  A ,  Schwartzman 
 A . National Hospital Discharge Survey: 2007 summary. National 
Health Statistics Reports; No 29. Hyattsville, MD: National Center 
for Health Statistics.  http://www.cdc.gov/nchs/data/nhsr/nhsr029.
pdf. Published 2010 . Accessed December 15,  2013 . 
  16 .  Klein  RJ ,  Schoenborn  CA .  Age Adjustment Using the 2000 
Projected US Population. Healthy People 2010 Statistics Notes, 
No. 20 .  Hyattsville, MD :  US Department of Health and 
Human Services, CDC, National Center for Health Statistics ; 
 2001 . 
  17 .  Gillum  BS ,  Graves  EJ ,  Kozak  LJ . Trends in hospitalization: United 
States, 1988-92. National Center for Health Statistics website. 
 http://www.cdc.gov/nchs/data/series/sr_13/sr13_124.pdf. Published 
1996. Accessed December15,  2013 . 
  18 .  Frost  AE ,  Badesch  DB ,  Barst  RJ ,  et al .  Th e changing picture of 
patients with pulmonary arterial hypertension in the United States: 
how REVEAL diff ers from historic and non-US Contemporary 
Registries .  Chest .  2011 ; 139 ( 1 ): 128 - 137 .  
  19 .  Lilienfeld  DE ,  Rubin  LJ .  Mortality from primary pulmonary hyper-
tension in the United States, 1979-1996 .  Chest .  2000 ; 117 ( 3 ): 796 - 800 . 
  20 .  Davis  KK ,  Lilienfeld  DE ,  Doyle  RL .  Increased mortality in African 
Americans with idiopathic pulmonary arterial hypertension .  J Natl 
Med Assoc .  2008 ; 100 ( 1 ): 69 - 72 . 
  21 .  Yaqub  A ,  Chung  L .  Epidemiology and risk factors for pulmonary 
hypertension in systemic sclerosis .  Curr Rheumatol Rep .  2013 ; 15 ( 1 ):
 302 .  
  22 .  Gladwin  MT ,  Sachdev  V ,  Jison  ML ,  et al .  Pulmonary hypertension 
as a risk factor for death in patients with sickle cell disease .  N Engl J 
Med .  2004 ; 350 ( 9 ): 886 - 895 .  
  23 .  O’Callaghan  DS ,  Humbert  M .  A critical analysis of survival in 
pulmonary arterial hypertension .  Eur Respir Rev .  2012 ; 21 ( 125 ):
 218 - 222 .  
  24 .  Badesch  DB ,  Raskob  GE ,  Elliott  CG ,  et al .  Pulmonary arterial 
hypertension: baseline characteristics from the REVEAL Registry . 
 Chest .  2010 ; 137 ( 2 ): 376 - 387 .  
  25 .  Kawut  SM ,  Taichman  DB ,  Archer-Chicko  CL ,  Palevsky  HI , 
 Kimmel  SE .  Hemodynamics and survival in patients with pul-
monary arterial hypertension related to systemic sclerosis .  Chest . 
 2003 ; 123 ( 2 ): 344 - 350 .  
  26 .  Austin  ED .  Gender, sex hormones, and pulmonary arterial hyper-
tension .  Advances in Pulmonary Hypertension .  2011 ; 10 ( 3 ): 160 - 166 . 
  27 .  Kawut  SM ,  Horn  EM ,  Berekashvili  KK ,  et al .  New predictors of out-
come in idiopathic pulmonary arterial hypertension .  Am J Cardiol . 
 2005 ; 95 ( 2 ): 199 - 203 .  
  28 .  Poms  AD ,  Turner  M ,  Farber  HW ,  Meltzer  LA ,  McGoon  MD . 
 Comorbid conditions and outcomes in patients with pulmo-
nary arterial hypertension: a REVEAL registry analysis .  Chest . 
 2013 ; 144 ( 1 ): 169 - 176 .  
  29 .  Bolignano  D ,  Rastelli  S ,  Agarwal  R ,  et al .  Pulmonary hypertension 
in CKD .  Am J Kidney Dis .  2013 ; 61 ( 4 ): 612 - 622 .  
  30 .  Murphy  SL ,  Xu  JQ ,  Kochanek  KD . Deaths: fi nal data for 2010. 
Hyattsville, MD: National Center for Health Statistics.  http://www.
cdc.gov/copd/data.htm . Published 2013. Accessed December 9, 
2013. 
  31 . Centers for Disease Control and Prevention, Division for Heart 
Disease and Stroke Prevention.  Interactive Atlas of Heart Disease 
and Stroke . Centers for Disease Control and Prevention website. 
 http://www.cdc.gov/dhdsp/maps . Accessed December 22, 2013. 
  32 .  Ling  Y ,  Johnson  MK ,  Kiely  DG ,  et al .  Changing demographics, 
epidemiology, and survival of incident pulmonary arterial 
hypertension: results from the pulmonary hypertension registry 
of the United Kingdom and Ireland .  Am J Respir Crit Care Med . 
 2012 ; 186 ( 8 ): 790 - 796 .  
  33 .  Shimony  A ,  Fox  BD ,  Afi lalo  J ,  Rudski  LG ,  Hirsch  A ,  Langleben  D . 
 Pulmonary arterial hypertension in the elderly-clinical charac-
teristics and long-term survival .  Lung .  2012 ; 190 ( 6 ): 645 - 649 .  
  34 .  Merrill  CT ,  Nagamine  M ,  Elixhauser  A . Hospital stays involving 
chronic pulmonary heart disease, 2005. HCUP Statistical Brief 
No. 43.  http://www.hcup-us.ahrq.gov/reports/statbriefs/sb43.
pdf. Published December 2007. Accessed December 15,  2013 . 
